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Background: The Breast Cancer Resistance Protein (BCRP/ABCG2) is one member of ABC transporters proteins
super family responsible of drug resistance. Since data on ABCG2 expression in liver malignances are scanty, here
we report the expression of ABCG2 in adult human hepatocellular carcinoma (HCC) in both in vivo and in vitro
models with different degree of malignancy.
Methods: In cell lines derived from human hepatocellular carcinoma, ABCG2 gene expression was assessed by
reverse transcription quantitative real time PCR and function by Hoechst 33342 efflux assay; protein content was
assessed by SDS-PAGE Western blot.
Results: ABCG2 expression was found to be highest in the most undifferentiated cell lines, and this was related
with a higher functional activity. ABCG2 expression was sensitive to antineoplastic drugs since exposure to 5 μM
doxorubicin for 24 hours resulted in significant up-regulations of ABCG2 in all cell lines, particularly in those lines
with low basal ABCG2 expression (p<0.01). The gene expression was also investigated in 51 adult liver tissues with
HCC and related cirrhosis; normal liver tissue was used as control. ABCG2 gene expression was higher in HCC than
both cirrhotic paired tissue and normal tissue. This up-regulation was greater (p<0.05) in pathological poorly
differentiated grade G3/G4 than in well-differentiated G1/G2 HCC.
Conclusions: Our results suggest a correlation of ABCG2 gene expression and differentiation stage both in human
and HCC derived cell lines. The rapid up-regulation of ABCG2 to exposure to doxorubicin emphasizes the
importance of this transporter in accounting for drug resistance in liver tumors.
Keywords: Liver cancer, Drug resistance, Gene expression, DoxorubicinBackground
Primary liver cancer is one of the most common cancers
in the world and the third cause of cancer-related death
[1]. Hepatocellular carcinoma (HCC) accounts for around
85-95% of all PLC cases. Targeted systemic therapies to
treat HCC patients with advanced stages had become one
of urgent needs in the management of HCC [2]. However,
systemic therapies also have been faced many obstacles,
such as drug toxicity and drug resistance.* Correspondence: caecilia.sukowati@csf.units.it
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reproduction in any medium, provided the orThe Breast Cancer Resistance Protein (ABCG2/BCRP/
MXR) is one member of the ATP-Binding Cassette (ABC)
transporters superfamily proteins [3]. One of the key functions
of ABC transporter is related with the cell resistance to expos-
ure of external compounds, exporting the drug out of the cells
thus maintaining the intracellular drug compound below toxic
level. ABCG2 protein is widely expressed in tissues, mainly in
placenta, epithelium of small intestine and colon, liver canali-
cular membrane and breast [4]. Furthermore, ABCG2 is also
expressed in the epithelium of the prostate and bladder, endo-
cervical cells of uterus, kidney tubules and others tissues [5].
The association between ABCG2 and cancer has been
extensively studied. The ABCG2 protein was observed in
a wide variety of tumors [6] and shown to be involved inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agents [7,8]. However, even though there are several
reports of ABCG2 in liver cancer [9-12], it is still needed
to be expanded and its correlation with clinical finding is
important to be explored. The ABCG2 expression was
found to be high in HCC [10] and was reported to in-
crease following chemotherapy in hepatoblastoma patients
[13]. In glioma, ABCG2 expression is related with patho-
logical grade, tissues differentiation and resistance to
mitoxantrone [14].
In recent studies, ABCG2 expression has been also
associated with stem cells and cancer stem cells, both in
circulating and solid cancers. Side population (SP) of
stem cells is a population of cells having the ability to
export Hoechst 33342 dye, an activity related with cells
resistance [15]. In HCC, the SP cells sorted from several
cell lines were associated with the metastatic potentials
and therapeutic-resistance [16]. Zhou et al. demon-
strated that the ABCG2/Bcrp1 is the molecular deter-
minant for SP [17,18] and SP of hepatic oval cells was
also defined by ABCG2/BCRP1 in the rat model [19].
Furthermore, cells expressing ABCG2 might play a cen-
tral role in hepatocarcinogenesis, in which ABCG2+ cells
could generate both ABCG2+ and ABCG2- cells,
whereas ABCG2- cells bore only ABCG2- cells [20].
Collectively these studies indicated the relevance of
ABCG2 in several human malignancies and its associ-
ation with drug resistance and cells differentiation. We
here report on the ABCG2 mRNA level and activity in
both in vitro and in vivo models consisting of human
hepatic cell lines and human samples of HCC to investi-
gate the role of this transporter, particularly its role in




Human liver cell lines IHH, HepG2, HuH-7 and JHH-6
were used as in vitro models of HCC cell lines with dif-
ferent degree of morphologic differentiation. The
immortalized hepatocyte line IHH was kindly provided
by Dr. Trono (Lausanne, Switzerland) [21] while human
HCC cell lines HuH-7 (JCRB0403) and JHH-6
(JCRB1030) were obtained from the Japan Health Sci-
ence Research Resources Bank (HSRRB, Tokyo, Japan).
The HepG2 cell line was obtained from the Istituto Zoo-
profilattico Sperimentale della Lombardia e dell’Emilia
Romagna (IZSLER, Brescia, Italy).
The IHH cells were grown in DMEM-F12 medium
supplemented with 10% (v/v) fetal bovine serum (FBS),
1% antibiotics, 1% L-glutamine, 1 μM dexamethasone
and 5 μg/mL insulin. The HepG2 and HuH-7 cells were
grown in DMEM medium (high glucose) supplemented
with 10% (v/v) FBS, 1% L-glutamine and 1% antibiotics.The JHH-6 cells were grown in Williams’ E medium
supplemented with 10% (v/v) FBS, 1% L-glutamine and
1% antibiotics. The cultures were maintained at 37°C in
a humidified 5% CO2 incubator and when they reached
80% - 90% confluence they were routinely expanded by
0.05% trypsin detachment.
Human tissue samples
Human liver tissues were collected from HCC patients
undergoing liver resections or orthotopic liver transplan-
tations and normal donor liver in the similar age group
as control. A total of 51 (23 HCC, 21 cirrhosis, 7 normal
tissues) liver tissues were analyzed. Fifteen paired sam-
ples HCC and cirrhosis were obtained from the same pa-
tient (70% of all HCC tissues analyzed). The tissues were
snap-frozen in liquid nitrogen and stored in −80°C be-
fore further processing. The diagnosis of patients was
established on international criteria together with its
Edmondson Steiner HCC grading [22] and other clinical
findings. Informed consent to participate to the study
was obtained from each patient or by a legal representa-
tive and the protocol was approved by the ethical com-
mittee of the University of Trieste.
In vitro cytotoxicity test
The cytotoxic effects of doxorubicin hydrochloride (Dox),
verapamil hydrochloride, Hoechst 33342 (Sigma-Aldrich,
St Louis, USA) and Rhodamine 123 (Rho123; Invitro-
gen, Milan, Italy) were assessed by 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
dye reduction test [23]. The cells were seeded in concen-
tration 20,000 cells/cm2 in 24-well plates for the corre-
sponding time. The dose of Dox, verapamil, Hoechst, and
Rho123 ranged from 0 to 10.0 μM, 0 to 20 μM, 0 to 5 μg/
mL, and 0 to 20 μg/mL, respectively. For Dox cytotoxicity
test, the exposure time was 24 hours, whereas for verap-
amil, Hoechst and Rho123 the exposure time was tested
at 30, 90 and 180 minutes as the required time to perform
the dye exclusion assay. The absorbance of the untreated
cells was taken as 100% survival.
Total RNA isolation and reverse transcription
Total RNA from cell lines and tissues samples was
extracted using the TriReagent solution (Sigma–Aldrich)
according to the manufacture’s protocol. The RNA pellet
was dissolved in nuclease-free water and stored at
−80° C until further analysis. RNA was quantified at 260
nm in a Beckman Coulter DUW730 spectrophotometer
(Fullertone, CA, USA). The RNA purity was evaluated
according the MIQE guidelines [24] by measuring the
ratio A260/A280 with appropriate purity values between
1.8 and 2.0. The integrity of RNA was assessed on stand-
ard 1% agarose/formaldehyde gel. The reverse transcrip-
tion of 1 μg of total RNA was performed with an iScript
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the manufacture’s suggestions. A total of 20 μL volume
reaction was conducted in a thermocycler (Gene Amp
PCR System 2400, Perkin-Elmer, Boston, MA, USA) at
25°C for 5 min, 42°C for 30 min, 85°C for 5 min. The
cDNA was conserved at −20°C until used.
Quantitative real time RT-PCR (RT-qPCR)
The RT-qPCR of gene ABCG2 and ABCB1 was per-
formed according to the iQ SYBR Green Supermix
protocol (Bio-Rad). PCR amplification was carried out in
15 μL reaction volume containing 25 ng of cDNA, 1x iQ
SYBR Green Supermix (100 mM KCl; 40 mM Tris–HCl;
pH 8.4; 0.4 mM each dNTP; 50 U/mL iTaq DNA poly-
merase; 6 mM MgCl2; SYBR Green I; 20 mM fluores-
cein; and stabilizers) and 250 nM gene specific sense
and anti-sense primers (Table 1). Reactions were run
and analyzed on a Bio-Rad iQ5 multi color real-time
PCR detection system (IQ5 software version 3.1) to-
gether with reference genes. Cycling parameters were
determined and analyzed using the Pfaffl modification of
the ΔΔCt equation with taking accounts to the efficiency
of the reaction [25]. Primer sets were designed using the
Beacon Designer 7.9 (Premier Biosoft International, Palo
Alto, CA, USA) across two exons to avoid contamin-
ation of genomic DNA and reference genes 18S-rRNA
and β-actin were used to normalize target gene expres-
sion. Melting curve analysis and agarose gel electrophor-
esis were carried out to asses templates specificity.
Western blot
After 5 μM Dox treatment for 24 hours, cells were
washed with PBS at room temperature. The protein was
extracted using cell lysis buffer (PBS containing 1% v/v
of a protease inhibitor cocktail and 2 mM phenylmethyl-
sulfonylfluoride). Protein concentration was determined
by copper (II) sulphate solution and bicinchonic acid
(Sigma-Aldrich) protein assay following the manufac-
turer’s instructions.
A total of 30 μg protein were size-separated, together
with molecular weight standard by SDS–PAGE using a
Mini Protein III Cell (Bio-Rad, Hercules, CA, USA).
After SDS–PAGE, proteins were electro-transferred with
a semi-dry blotting system onto immune-blot PVDF
membranes using a Mini Trans-Blot Cell (Bio-Rad).Table 1 List of primer sequences for the quantification of spe
samples tissues




18S-rRNA NR_003286 TAACCCGTTGAACCCCATTMembrane was incubated overnight at 4°C with targeted
antibodies in T-TBS buffer (Tris 20 mM, Tween 20,
0.2%, NaCl 500 nM, pH 7.5). The peroxidase reaction
was obtained by exposure of membrane in the ECL-Plus
Western blot detection system solutions (ECL Plus
Western blotting Detection Reagents, GE-Healthcare
Bio-Sciences, Italy). List of antibodies was described in
Table 2.
Hoechst 33342 efflux assay
The activity of ABCG2 in cell lines IHH, HepG2, HuH-7
and JHH-6 was assessed using Hoechst 33342 efflux
assay with modification from previous report [27]. Single
cells suspension and monolayer cells were given sterile 1
to 20 μM final concentration of verapamil incubated for
30 minutes in 37°C. After incubation, 5 μg/mL Hoechst
33342 was added, and the cells incubated for 90 minutes
in 37°C. The reaction was stopped by incubating the
cells on ice for 5 minutes. The Hoechst 33342 efflux was
measured by spectrofluorometer (Jasco FP-770, Mary-
land, USA and Hidex Chameleon - Driver 4.34, Turku,
Finland) for suspension and monolayer cells, respect-
ively. The measurement was performed on 355 nm exci-
tation and 460 nm emission wavelength. To confirm the
ABCB1 activity, the internal accumulation of Rho123,
was performed by FACSCalibur flow cytometer (Beckton
Dickinson, NJ, USA). A total of 10,000 events were ana-
lyzed per sample.
Statistical analysis
Box plot graphics and statistical analysis were con-
structed using software SigmaPlot Version 11.0 (Systat
Software, Inc., Chicago, USA). The student’s t test was
performed for statistical comparison between groups.
Value of p<0.05 was regarded as statistically significant.
Results
Modulation of the ABCG2 gene and protein expression by
doxorubicin
To investigate the ABCG2 expression according to cell
differentiation, 4 human-derived hepatic cell lines with
different degree of differentiation were analyzed. The ex-
pression of immortalized normal human hepatocytes
IHH was defined as control 1.00. The highest level of
ABCG2 folds mRNA expression compared to IHH wascific genes by RT-qPCR in hepatic cell lines and clinical
Primer reverse Ref.
AGTC GTTGGTCGTCAGGAAGAAGAG This study
TG AATTACAGCAAGCCTGGAACC This study
CACGATGGAGGGGAAGACGG This study
CCATCCAATCGGTAGTAGCG [26]
Table 2 List of antibodies
Antibody Clone MW kDa
ABCG2/BCRP BXP53 (Abcam, Cambridge, MA, USA) 72
ABCB1/MDR1 C219 (Abcam, Cambridge, MA, USA) 170
Actin A2066 (Sigma-Aldrich, St. Louis, MO, USA) 42
Anti rabbit IgG peroxidase P0448 (Dako, Glostrup, Denmark)
Anti rat IgG peroxidase P0450 (Dako, Glostrup, Denmark)
Anti mouse IgG peroxidase P0260 (Dako, Glostrup, Denmark)
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± 6.00), followed by the more differentiated cells HepG2
(53.52 ± 19.06) and HuH-7 (35.07 ± 10.96) with p<0.01.
In line with the mRNA results, ABCG2 protein (72 kDa)
was detected in tumoral cell lines HuH-7, HepG2, and
JHH-6, but not or very weak in IHH (Figure 1A). TheFigure 1 The expression of ABCG2 in hepatic cell lines. A. The
basal ABCG2 mRNA and protein expression in human hepatic cell
lines IHH, HuH-7, HepG2 and JHH-6. The data represented the
mean ± SD of minimum three independent experiments. Statistical
student’s t test: mRNA **p<0.01 to IHH, protein ##p<0.01 to IHH. B.
The folds of ABCG2 mRNA up-regulation after exposure to 5 μM Dox
for 24 hours compared to basal expression considered (1.00).
Statistical students’ t test: ** p<0.01 to basal expression of each cell
lines. The mRNA expression was normalized to reference genes
18S-rRNA and β-actin. Protein blot showing a representative Western
Blot of ABCG2 (72 kDa) and ABCB1 (170 kDa) protein.
Symbol: – control (basal level), + Dox.protein expression in JHH-6 is 11.5 ± 1.5 folds higher
compared to IHH (p<0.01).
We then assessed the effect of ABCG2 expression after
exposure to Dox. When exposed to 5 μM Dox for 24
hours, 50% cell population in all cell lines tested died. In
the surviving cells of each cell line, the exposure to Dox
induced an up-regulation of ABCG2 mRNA. Of notice
the extent of the up-regulation was inverse to the basal
level of expression as IHH and HuH-7 showed a signifi-
cant increment of gene expression (15.25 ± 4.45 and
9.36 ± 0.48 folds, respectively, p<0.01) as compared to
HepG2 and JHH-6 which the expression was unchanged
(1.14 ± 0.68 and 1.38 ± 1.58 folds, respectively). In line
with the gene expression, ABCG2 protein was weakly
detected in IHH cells at basal condition, but it became
detectable after exposure to Dox. The same occurred in
HuH-7 while no difference was observed in JHH-6 cells
where the treatment did not induce a significant over-
expression of the transporter. However, even though
there was a striking ABCG2 up-regulation compared to
their basal level, the level of ABCG2 in IHH after Dox
did not reach the basal level of HuH-7, HepG2, and
JHH-6, still about a half of basal HuH-7 expression
(Figure 1B).
The functional activity of ABCG2
To define the activity of the ABCB1 and ABCG2 protein
in the cell lines, the Hoechst 33342 efflux assay was
determined. Preliminary experiments showed no effect
on cell viability (MTT test) by verapamil, Hoechst and
Rho123, to all cell lines, on working concentration of 10
μM, 5 μg/mL, and 10 ug/mL (96.6 ± 5.3%, 90.6 ± 7.4%,Table 3 The efflux capacity of the HCC cell lines in
exporting Hoechst 33342
HCC lines Hoechst 33342 (μg/mL)
2.5 5.0 10.0
HuH-7 100.0 ± 6.4 88.4 ± 5.5 53.0 ± 2.8
HepG2 100.0 ± 6.2 74.7 ± 3.1 51.2 ± 2.8
JHH-6 100.0 ± 5.8 80.1 ± 2.1 53.7 ± 4.0
The increase of Hoechst 33342 concentration decreased intracellular dye
accumulation in all HCC cell lines tested. The intracellular dye intake of 2.5 μg/
mL as lowest dye concentration was considered as 100.0%. The data
represented the mean ± SD of three independent experiments.
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also the level of basal ABCB1 expression in these cell
lines. The ABCB1 mRNA expression in IHH and JHH-6
were really low, more than 1000 times lower compared
to those of HuH-7 and HepG2. ABCB1 protein expres-
sion was shown in Figure 1B.
As shown in Table 3, the increase of Hoechst concen-
tration (2.5 – 10.0 μg/mL) increased the activity of these
two transporters to export dyes. This was defined by the
decrease of Hoechst intracellular dye accumulation.Figure 2 Functional capacity of ABCG2. A. The uptake of
intracellular Hoechst 33342 accumulation measured by
spectrofluorometry. The difference in intracellular dye accumulation
with and without ABCB1 inhibitor verapamil was observed to be
lower in JHH-6 followed by HepG2 and HuH-7 indicating major
functional activity of ABCG2 in JHH-6. Cells without verapamil =
100.0%. B. Representative histogram plots showing the intracellular
fluorescence of Rho123 in 10,000 events by FACS analysis. The data
represented the mean ± SD of minimum three independent
experiments. C. The dose-dependent intracellular Hoechst 33342
accumulation in monolayer HuH-7 and JHH-6 cells. Statistical
student’s t test: *p<0.05.These evidences showed the capacity of both transpor-
ters to efflux the dyes out of the cells as a mechanism of
cells toxicity defense mechanism.
Since the extracellular extrusion Hoechst 33342 is
accounted by two ABC proteins (ABCB1 and ABCG2),
to establish the relative role of ABCG2 the assay was
also performed in the presence of verapamil, a potent
ABCB1 but a weak ABCG2 inhibitor [30]. In the HCC
cell lines which have both ABCB1 and ABCG2, the low-
est differential Hoechst fluorescence signal between cells
with and without verapamil was found in cells JHH-6,
indicating the ABCG2 in this cell line is dominantly re-
sponsible of the dye efflux. The result of Rho123 efflux
measurement by FACS confirmed the functionality of
ABCB1 was observed higher in HuH-7 and HepG2
(Figure 2A). A dose dependent Hoechst 33342 internal
dye accumulation with the presence 1 to 20 μM verap-
amil in monolayer cells gave similar result (Figure 2B).
ABCG2 expression in vivo
To confirm the data found in the cell lines in an in vivo
series, we measured the quantity of ABCG2 mRNA in
human samples collected from patient with HCC and
cirrhosis. The ABCG2 mRNA levels in the 51 tissues
samples were estimated by RT-qPCR and expressed in
arbitrary units (au); a sample obtained from normal
human liver was considered as 1.00 au. As shown in
Figure 3A, ABCG2 expression was found to be rather
variable in all groups and in particular in HCC patients.
The ABCG2 expression were found to be more
restricted in normal and cirrhotic tissues compared to
HCC
When HCC patients were divided according to the
Edmondson Steiner HCC grading system, the expression
of ABCG2 was found to be higher in HCC with poorly
differentiated HCC G3/G4 (n=6) as compared to well-
and moderately-differentiated HCC G1/G2 (n=13)
(p<0.05). In 15 paired samples, the up-regulation of
ABCG2 in HCC compared to its cirrhotic tissue was
consistently found to be higher in G3/G4 HCC (ratio
3.24 ± 2.08 folds) than in G1/G2 HCC (ratio 1.25 ± 1.06
folds) (p<0.01) as shown in Figure 3B. This significance
was not observed for ABCB1 gene. There was no correl-
ation of ABCG2 with other clinical findings such as
MELD and CTP score, etiology, alpha fetoprotein and
albumin level, and vascular invasion.
Discussion
The non-responsiveness of cancer cells to chemothera-
peutic regiments has been a major obstacle in the treat-
ment of cancers. The survival rate for HCC patients in
advanced stages which could not treated with surgical
procedures (including liver transplantation) has not been
changed for 30 years [28]. One of the important issues
Figure 3 The expression of ABCG2 mRNA in HCC tissues. A. The
general distribution of ABCG2 mRNA expression in HCC and normal
liver. Normal liver (N; n = 7), cirrhotic tissue of HCC (n = 21), and
tumoral tissue of HCC (n = 23). B. The up-regulation of ABCG2
mRNA in the HCC compared to its cirrhotic paired tissues from 15
paired individuals with histological G1/G2 and G3/G4 grade. The
mRNA expression was normalized to reference genes β-actin and
18S-rRNA. A normal liver was considered as 1.0 au. Statistical
student’s t test: ** p<0.01.
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of ABC transporters proteins, including ABCG2.
Due to the inconclusive data on the role of ABCG2 in
HCC we assessed the functional and gene expression of
this ABC transporter in two different but related systems
such as a series of human derived liver cell lines and
patients with HCC and cirrhosis. For the in vitro model
4 differently differentiated hepatic cell lines were used.
Three derived from HCC while one originates from a
normal adult liver. The ABCG2 mRNA expression in
tumoral lines was higher than in immortalized normal
hepatocyte (IHH) and this was paralleled by the protein
contents. Of notice was the effect observed when the
cells were exposed to 5 μM Dox. This treatment induced
an up-regulation of both gene expression and proteincontent in all cell lines, but the up-regulation was in-
versely proportional to the basal level of expression. This
behavior suggests that in the presence of toxic drug,
ABCG2 is induced to export the drug from the cell and
to prevent cytotoxicity as one of the major defense
mechanisms and that this effect is maximal when the
basal level of the expression is low. The data we
observed in HepG2 cells agree with a previous report in
which ABCG2 mRNA was up-regulated in Dox-resistant
HepG2 [29].
To assess the activity of ABCG2 in cancer cell lines, we
performed a functional assay using the Hoechst 33342
test. The efflux of Hoechst 33342 is accounted by both
ABCG2 and ABCB1 transporters, and verapamil had been
shown to effectively inhibit ABCB1 but not ABCG2 [30].
The addition of verapamil resulted in the increase of intra-
cellular Hoechst 33342 in the well differentiated HepG2
and HuH-7 cells but not in the poorly differentiated cells
(JHH-6). This data points to the conclusion that in the
poorly differentiated HCC cell line, the efflux is mainly de-
pend on the ABCG2 activity while in the more differen-
tiated ones, drug export is also accounted by the activity
of ABCB1. This conclusion is in line with very high
ABCB1 expression in both HepG2 and HuH-7 cells. This
finding indicates that a high expression of ABCG2 tran-
scription is associated with functional role of the trans-
porter which results in the protection of the cell from
doxorubicin-induced cytotoxicity.
To compare the data obtained in vitro, we studied the
ABCG2 mRNA expression in samples of adult normal
liver and tissues obtained from HCC patients. There are
several limitations in this type of studies such as the ef-
fect of the different treatments to which each patient
undergoes before being considered for hepatic resection
or transplantation. Our data in human tissues samples
show a rather high variation in ABCG2 expression, as
expected. The large variations of intra- and inter-groups
ABCG2 expression observed in this study had also been
reported in acute leukemia [31], breast cancer [32] and
lung cancer [33]. We believe that these variations are
likely linked to several factors such as age, sex, type of
the drugs, duration of the treatments, severity of the dis-
eases, and many others. In line with this conclusion is
the observation that when we compared the expressions
of normal adult liver with that obtained from children,
ABCG2 expression was higher in the adults (data not
shown), suggesting that ABCG2 expression is age-
related and dependent to drug exposure which obviously
increases with age.
The overall distribution showed that the expression of
the ABCG2 mRNA was slightly higher and more dis-
persed in HCC and cirrhotic tissues as compared to nor-
mal tissues, in line with a previous report [10].
Interestingly, the ABCG2 mRNA expression was higher in
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60% of HCC patients. Of notice was the observation that
this up-regulation was consistently observed in poorly dif-
ferentiated pathological grade G3/G4 than in G1/G2 HCC
tissue. This is different from what described by Gupta
et al. who reported in 3 specimens of liver cancers that
both the mRNA and protein level of ABCG2 were
decreased [34]. The discrepancy suggests that the ABCG2
expression is variable and dependent by the tissue type,
even in the single individual due to variability of HCC tis-
sues profile. A relationship between cell differentiation
and ABCG2 expression had been previously reported in
other cell lines. A high level of functional ABCG2 was
detected in undifferentiated human embryonic cells
and decreased during cellular differentiation [35]. In
hematopoietic system, the ABCG2 expression is confined
to the most immature progenitor cells and down-
regulated at the committed progenitor level [36]. Recent
data showed that knock-down of ABCG2 inhibited breast
cancer and lung cancer cells proliferation, suggesting the
role of ABCG2 in maintenance the cancer cells [37].
Our finding reemphasized the importance of intrinsic
factors like age, differentiation, and disease status in the
expression of drug-transporters in human tissues. Our
data expand the previous report showing that ABCG2
protein and mRNA were higher in HCC [10] and that in
hepatoblastoma patients the transporter was up-
regulated following chemotherapy [13]. For the ABCG2
and pathological grade of cancer, our data in HCC is
concordant with those observed in glioma [14].
Conclusions
Our findings demonstrated an higher expression of the
ABCG2 in liver diseases compared to normal tissue and
possibly more important, in HCC where the genetic and
functional up-regulation is more marked in less differen-
tiated tumors. The up-regulation of ABCG2 observed in
response to drug therapy underlines the importance of
this transporter to account for the drug resistance and
points the needs to explore its expression in liver dis-
eases, HCC in particular.
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